A real-world breast cancer imaging and biomarker development theme emerged from an analysis of post-therapy esophageal tissue showing that cancer treatments can alter the landscape of somatic mutations in adjacent normal epithelium. The Nature Genetics work suggests sequencing treatment-exposed normal tissues could reveal genes behind therapy response, side effects, and resistance. In imaging, Nectin-4-targeted PET was reported to outperform FDG PET/CT for aggressive breast cancer, which could reduce uncertainty in staging and treatment planning for triple-negative disease. Both directions—treatment-specific mutation landscapes and target-relevant PET—aim to tighten the link between diagnostic readouts and actionable biology.